Rash from EGFR Inhibitors: Opportunities and Challenges for Palliation

    July 2008 in “ Current Oncology Reports ”
    Benjamin Solomon, Aminah Jatoi
    Studysummary EGFR cancer drugs often cause a rash, which can lead to distress and isolation, but may also improve outcomes for some cancer patients. Current treatments for the rash are limited, but a compound called menadione shows promise.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on link.springer.com →
    Discuss this study in the Community →

    Research cited in this study 2

    1. Classification and Management of Skin, Hair, Nail, and Mucosal Side Effects of Epidermal Growth Factor Receptor Inhibitors European journal of cancer · 2007
    2. Follicular and Epidermal Alterations in Patients Treated with ZD1839 (Iressa), an Inhibitor of the Epidermal Growth Factor Receptor British journal of dermatology/British journal of dermatology, Supplement · 2002